1. Home
  2. NCRA vs CDIO Comparison

NCRA vs CDIO Comparison

Compare NCRA & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.21

Market Cap

5.6M

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$1.81

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
CDIO
Founded
2002
2017
Country
Taiwan
United States
Employees
N/A
17
Industry
Farming/Seeds/Milling
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
CDIO
Price
$0.21
$1.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
644.0K
83.7K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,627,944.00
N/A
Revenue This Year
N/A
$171,906.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.18
52 Week High
$2.40
$7.91

Technical Indicators

Market Signals
Indicator
NCRA
CDIO
Relative Strength Index (RSI) 35.23 41.18
Support Level $0.18 $1.69
Resistance Level $0.24 $2.08
Average True Range (ATR) 0.03 0.14
MACD 0.01 0.04
Stochastic Oscillator 53.85 27.67

Price Performance

Historical Comparison
NCRA
CDIO

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Share on Social Networks: